The EGFR mutation status has clinical significance as a biomarker and can be used to determine the best treatment for advanced NSCLC; thus, most studies that have evaluated novel analysis techniques have focused on detecting EGFR mutations in blood samples from NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.